2023 | Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial | Herbst, Roy S; Wu, Yi-Long; John, Thomas; Grohe, Christian; Majem, Margarita; Wang, Jie; Kato, Terufumi; Goldman, Jonathan W; Laktionov, Konstantin; Kim, Sang-We; CHONG-JEN YU ; Vu, Huu Vinh; Lu, Shun; Lee, Kye Young; Mukhametshina, Guzel; Akewanlop, Charuwan; de Marinis, Filippo; Bonanno, Laura; Domine, Manuel; Shepherd, Frances A; Urban, Damien; Huang, Xiangning; Bolanos, Ana; Stachowiak, Marta; Tsuboi, Masahiro | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 95 | 32 | |
2022 | LIBRETTO-432, a phase III study of adjuvant selpercatinib or placebo in stage IB-IIIA RET fusion-positive non-small-cell lung cancer | Tsuboi, Masahiro; Goldman, Jonathan W; Wu, Yi-Long; Johnson, Melissa L; Paz-Ares, Luis; CHIH-HSIN YANG ; Besse, Benjamin; Su, Weiji; Chao, Bo H; Drilon, Alexander | Future oncology (London, England) | 9 | 7 | |